The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis

Bioscience Reports - Tập 38 Số 1 - 2018
Yi Wang1, Zhiqiang Qin1, Guo‐Qing Zhu1, Chen Chen1, Yichun Wang1, Xianghu Meng1, Ninghong Song1
1Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China

Tóm tắt

The recommended therapy by EAU guidelines for metastatic prostate cancer (mPCa) is androgen deprivation therapy (ADT) with or without chemotherapy. The role of radical prostatectomy (RP) in the treatment of mPCa is still controversial. Hence, a meta-analysis was conducted by comprehensively searching the databases PubMed, EMBASE and Web of Science for the relevant studies published before September 1st, 2017. Our results successfully shed light on the relationship that RP for mPCa was associated with decreased cancer-specific mortality (CSM) (pooled HR = 0.41, 95%CI = 0.36–0.47) and enhanced overall survival (OS) (pooled HR = 0.49, 95%CI = 0.44–0.55). Subsequent stratified analysis demonstrated that no matter how RP compared with no local therapy (NLT) or radiation therapy (RT), it was linked to a lower CSM (pooled HR = 0.36, 95%CI = 0.30–0.43 and pooled HR = 0.56, 95%CI 0.43–0.73, respectively) and a higher OS (pooled HR = 0.49, 95%CI = 0.44–0.56 and pooled HR = 0.46, 95%CI 0.33–0.65, separately). When comparing different levels of Gleason score, M-stage or N-stage, our results indicated that high level of Gleason score, M-stage or N-stage was associated with increased CSM. In summary, the outcomes of the present meta-analysis demonstrated that RP for mPCa was correlated with decreased CSM and enhanced OS in eligible patients of involved studies. In addition, patients with less aggressive tumors and good general health seemed to benefit the most. Moreover, no matter compared with NLT or RT, RP showed significant superiority in OS or CSM. Upcoming prospective randomized controlled trials were warranted to provide more high-quality data.

Từ khóa


Tài liệu tham khảo

Siegel, 2016, Cancer statistics, 2016, CA Cancer J. Clin., 66, 7, 10.3322/caac.21332

Xue, 2017, Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis, Oncotarget, 8, 23322, 10.18632/oncotarget.15056

Scardino, 2005, Update: NCCN prostate cancer clinical practice guidelines, J. Natl. Compr. Cancer Netw., 3, S29

Stenzl, 2008, Radical prostatectomy in advanced-stage and -grade disease: cure, cytoreduction, or cosmetics?, Eur. Urol., 53, 234, 10.1016/j.eururo.2007.10.048

Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur. Urol., 65, 467, 10.1016/j.eururo.2013.11.002

Kaplan, 2006, Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond, Cancer Metastasis Rev., 25, 521, 10.1007/s10555-006-9036-9

Cifuentes, 2015, Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer, Oncol. Rep., 34, 2837, 10.3892/or.2015.4319

Flanigan, 2004, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J. Urol., 171, 1071, 10.1097/01.ju.0000110610.61545.ae

Bookman, 2016, Optimal primary therapy of ovarian cancer, Ann. Oncol., 27, i58, 10.1093/annonc/mdw088

Kim, 2009, Tumor self-seeding by circulating cancer cells, Cell, 139, 1315, 10.1016/j.cell.2009.11.025

Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J. Urol., 193, 832, 10.1016/j.juro.2014.09.089

Swanson, 2006, Metastatic prostate cancer – does treatment of the primary tumor matter?, J. Urol., 176, 1292, 10.1016/j.juro.2006.06.069

Costa, 2016, Difference of opinion – radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: Yes, Int. Braz. J. Urol., 42, 876, 10.1590/S1677-5538.IBJU.2016.05.04

Ristau, 2016, Difference of opinion – radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: No, Int. Braz. J. Urol., 42, 880, 10.1590/S1677-5538.IBJU.2016.05.05

Swanson, 2006, Metastatic prostate cancer-does treatment of the primary tumor matter?, J. Urol., 176, 1292, 10.1016/j.juro.2006.06.069

Jr, 2007, Re: Metastatic prostate cancer-does treatment of the primary tumor matter?, Eur. Urol., 51, 852, 10.1016/j.eururo.2006.12.007

Mohler, 2014, Concept and viability of androgen annihilation for advanced prostate cancer, Cancer, 120, 2628, 10.1002/cncr.28675

Mathieu, 2017, Cytoreductive radical prostatectomy in metastatic prostate cancer: does it really make sense?, World J. Urol., 35, 567, 10.1007/s00345-016-1906-3

Williamson, 2002, Aggregate data meta-analysis with time-to-event outcomes, Stat. Med., 21, 3337, 10.1002/sim.1303

Tierney, 2007, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials, 8, 16, 10.1186/1745-6215-8-16

Stang, 2010, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur. J. Epidemiol., 25, 603, 10.1007/s10654-010-9491-z

Dersimonian, 1986, Meta-analysis in clinical trials, Control. Clin. Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Leyh-Bannurah, 2017, Local therapy improves survival in metastatic prostate cancer, Eur. Urol., 10.1016/j.eururo.2017.03.020

Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis, J. Urol., 194, 378, 10.1016/j.juro.2015.02.084

Shao, 2014, Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis, Eur. Urol., 65, 693, 10.1016/j.eururo.2013.05.023

Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur. Urol., 66, 602, 10.1016/j.eururo.2014.04.009

Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur. Urol., 65, 1058, 10.1016/j.eururo.2013.11.012

Antwi, 2014, Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis, Cancer Epidemiol., 38, 435, 10.1016/j.canep.2014.04.002

Parikh, 2017, Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer, Prostate, 77, 559, 10.1002/pros.23294

Moschini, 2017, Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis, Prostate Cancer Prostatic Dis., 20, 117, 10.1038/pcan.2016.63

Rusthoven, 2016, Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer, J. Clin. Oncol., 34, 2835, 10.1200/JCO.2016.67.4788

Veeratterapillay, 2017, Radical prostatectomy for locally advanced and metastatic prostate cancer, Ann. R. Coll. Surg. Engl., 99, 259, 10.1308/rcsann.2017.0031

Nakaoka, 2009, Meta-analysis of genetic association studies: methodologies, between-study heterogeneity and winner's curse, J. Hum. Genet., 54, 615, 10.1038/jhg.2009.95

Fossati, 2015, Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study, Eur. Urol., 67, 3, 10.1016/j.eururo.2014.08.056

Loppenberg, 2016, The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis, Eur. Urol., 72, 14, 10.1016/j.eururo.2016.04.031

Sooriakumaran, 2016, A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur. Urol., 69, 788, 10.1016/j.eururo.2015.05.023

Thông tin
Thông tin xuất bản

Bioscience Reports

Tập 38 Số 1

Thông tin tác giả